Education
About Us
Working with TipRanks
Follow Us
Tempus AI, Inc. Class A (TEM)
NASDAQ:TEM
TEM Stock Chart & Stats
$67.15
-$0.17(-0.45%)
At close: 4:00 PM EST
$67.15
-$0.17(-0.45%)
Day’s Range― - ―
52-Week Range$31.66 - $104.32
Previous CloseN/A
Volume1.41M
Average Volume (3M)3.51M
Market Cap
$12.32B
Enterprise Value$14.70B
Total Cash (Recent Filing)$759.64M
Total Debt (Recent Filing)$1.34B
Price to Earnings (P/E)―
Beta3.07
Next Earnings
Mar 02, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding172,863,460
10 Day Avg. Volume4,079,562
30 Day Avg. Volume3,506,778
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)97.15
Price to Sales (P/S)7.89
P/FCF Ratio-25.92
Enterprise Value/Market Cap1.19
Enterprise Value/Revenue13.30
Enterprise Value/Gross Profit21.67
Enterprise Value/Ebitda-163.81
Forecast
1Y Price Target
$86.00Price Target Upside28.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Commercial Traction And Customer ExpansionRecord contract wins combined with high customer revenue retention demonstrate strong commercial traction and successful expansion within existing accounts.
Data And Strategic PartnershipsPartnerships and data agreements with major pharmaceutical companies validate demand for the multimodal data platform and increase visibility to future data-driven revenue.
Testing Volume GrowthAnalyst notes accelerating oncology and hereditary testing volumes that support meaningful revenue expansion and broaden the company's addressable market.
Bears Say
Competitive And Scalability RiskIntense competition from established specialty labs and uncertain scalability beyond oncology could impede future market share growth and pressure margins.
Data Segment Visibility RiskLack of tangible research and development proof points for the Data segment makes it difficult for investors to assess value and heightens execution risk for data monetization.
Profitability And Capital RiskRisks around achieving sustainable profitability, retaining and acquiring customers, and the potential need for additional capital could lead to shareholder dilution and weigh on valuation.
TEM FAQ
What was Tempus AI, Inc. Class A’s price range in the past 12 months?
Tempus AI, Inc. Class A lowest stock price was $31.66 and its highest was $104.32 in the past 12 months.
What is Tempus AI, Inc. Class A’s market cap?
Tempus AI, Inc. Class A’s market cap is $12.32B.
When is Tempus AI, Inc. Class A’s upcoming earnings report date?
Tempus AI, Inc. Class A’s upcoming earnings report date is Mar 02, 2026 which is in 47 days.
How were Tempus AI, Inc. Class A’s earnings last quarter?
Tempus AI, Inc. Class A released its earnings results on Nov 04, 2025. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.172 by $0.062.
Is Tempus AI, Inc. Class A overvalued?
According to Wall Street analysts Tempus AI, Inc. Class A’s price is currently Undervalued.
Does Tempus AI, Inc. Class A pay dividends?
Tempus AI, Inc. Class A does not currently pay dividends.
What is Tempus AI, Inc. Class A’s EPS estimate?
Tempus AI, Inc. Class A’s EPS estimate is -0.04.
How many shares outstanding does Tempus AI, Inc. Class A have?
Tempus AI, Inc. Class A has 172,863,460 shares outstanding.
What happened to Tempus AI, Inc. Class A’s price movement after its last earnings report?
Tempus AI, Inc. Class A reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.172. Following the earnings report the stock price went down -2.639%.
Which hedge fund is a major shareholder of Tempus AI, Inc. Class A?
Currently, no hedge funds are holding shares in TEM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tempus AI, Inc. Class A Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$86.00 (28.07% Upside)
$86.00 (28.07% Upside)
Blogger Sentiment
Bullish
TEM Sentiment 75%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 220.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $283.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 1.8%
Last 30 Days ▼ 1.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
84.59%
12-Months-Change
Fundamentals
Return on Equity
-72.61%
Trailing 12-Months
Asset Growth
134.78%
Trailing 12-Months
Company Description
Tempus AI, Inc. Class A
Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies. In addition, it operates Next; Algos, a suite of algorithmic tests in oncology; Hub, a desktop and mobile platform for ordering, managing, and receiving tests and patient results; and Lens, a platform for researchers and scientists to find, access, and analyze Tempus data. The company has a strategic collaborations agreement with AstraZeneca and Pathos AI, Inc. to develop therapeutic programs in oncology. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
TEM Company Deck
TEM Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong growth in Genomics and significant achievements like positive adjusted EBITDA and successful data licensing deals. However, there were challenges such as the disruption caused by changes in the sales force and costs associated with the Paige acquisition. Overall, the positive achievements and strong growth trajectory indicate a healthy business outlook.View all TEM earnings summariesTEM Stock 12 Month Forecast
Average Price Target
$86.00
▲(28.07% Upside)
Technical Analysis
Ownership Overview
31.84% Insiders
8.24% Mutual Funds
0.11% Other Institutional Investors
46.68% Public Companies and Individual Investors